What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate the long-term safety profile of ixazomib in patients with multiple myeloma, amyloidosis, and lymphoma.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Open-label study assesses ixazomib safety in 32 patients, suggesting favorable findings for long-term therapy outcomes.

To evaluate the long-term safety profile of ixazomib in patients with multiple myeloma, amyloidosis, and lymphoma.
Open-label, multicenter, rollover study
Included 32 patients who previously tolerated ixazomib
Monitored treatment-emergent adverse events and other safety measures
71.9% received ixazomib monotherapy
68.8% experienced at least one treatment-emergent adverse event
No evidence of cumulative or late-onset toxicity observed

Yoon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Open-label study assesses ixazomib safety in 32 patients, suggesting favorable findings for long-term therapy outcomes.

To evaluate the long-term safety profile of ixazomib in patients with multiple myeloma, amyloidosis, and lymphoma.
Open-label, multicenter, rollover study
Included 32 patients who previously tolerated ixazomib
Monitored treatment-emergent adverse events and other safety measures
71.9% received ixazomib monotherapy
68.8% experienced at least one treatment-emergent adverse event
No evidence of cumulative or late-onset toxicity observed

Yoon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark